Raymond James raises Kymera Therapeutics target to $144 from $140
KYMR•Raymond James raised its price target for Kymera Therapeutics to $144 from $140.
Related News
Teck Resources Ltd: Canaccord Genuity cuts target price to C$87 from C$96.5
TECK•
DoorDash: MoffettNathanson cuts target price to $277 from $278
DASH•
Exponent, Inc.: JP Morgan raises target price to $100 from $90
EXPO•
Dexcom target price raised to $97 from $90 by Canaccord Genuity
DXCM•
FinWise Bancorp: Raymond James cuts target price to $15 from $16
FINW•